LEGN Penghasilan resik perusahaan legendbiotech.com

Profit volatility for Legend Biotech (LEGN) on the GURU.Markets chart is driven by significant regulatory challenges and a dependency on Johnson & Johnson, while the -0.09 metric reflects current dynamics. Growth is supported by a strategic alliance with pharma behemoths to implement CAR-T products; however, expansion rates are limited by laboratory development costs and the global distribution of innovative treatments.

LEGN Legend Biotech Corporation: Penghasilan resik ing interval 04.07.2022 - 29.10.2026

Rincian metrik keuangan lan pasar Legend Biotech Corporation (LEGN)

- rega saham lan konsensus proyeksi valuasi:

Bagan rega Legend Biotech Corp.|LEGN - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar Legend Biotech Corp.|LEGN - Nilai Perusahaan

- data ekuitas miturut neraca:

Nilai Buku Siji Saham Legend Biotech|LEGN - Aset Bersih Perusahaan|Koefisien Nilai Pasar marang Nilai Buku legendbiotech.com|LEGN - Gunggung Aset Perusahaan

- indikator beban utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi Legend Biotech|LEGN - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Legend Biotech Corp|LEGN - Gunggung utang perusahaan|Utang-utang marang nilai buku Legend Biotech Corp.|LEGN - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Legend Biotech|Likuiditas cepet legendbiotech.com

- data bathi bisnis lan rasio investasi:

LEGN - Penghasilan resik

Pambiji fundamental:LEGN Legend Biotech Corp.

Produk sing diprodhuksi Legend Biotech Inc.

Investors in Legend Biotech (LEGN) must evaluate the company's ability to generate cash flow amid the costs of scaling Car-T therapy and regulatory pressure. This metric measures the final financial result net of all operating expenses, allowing the company to determine real business efficiency and capital resilience against geopolitical risks over the long term through its net balance.

Pesaing utama